One-shot, low-dosage intratympanic gentamicin for Ménière's disease: Clinical, posturographic and vestibular test findings.
Background: Ménière’s disease has been remained as a difficult therapeutic challenge. The present study aimed to determine the effects of one-shot low-dosage intratympanic gentamicin on vertigo control, auditory outcomes and findings of computerized dynamic posturography and vestibular evoked myogenic potentials in patients with unilateral Ménière’s disease.
Methods: In a prospective clinical study, 30 patients with unilateral Ménière’s disease were treated with one-shot intratympanic injection of 20 milligrams gentamicin. Main outcome measures included clinical, audiometric, postural and vestibular outcomes evaluated 1 and 9 months after the treatment.
Results: Mean vertigo attacks frequency, pure tone average threshold and functional level scale significantly decreased after the treatment (P < 0.05). Effective vertigo control (class A and B) obtained in 95.8% of the patients. In total, 75% of patients reported decrease in both aural fullness and tinnitus. Vestibular evoked myogenic potentials became absent in all the patients but four of them. Posturographic scores were improved after the treatment.
Conclusion: One-shot low-dosage gentamicin was effective in controlling vertigo attacks in Ménière’s disease and has useful effects on aural fullness and tinnitus of patients as well. Postural and vestibular tests only have adjunctive role for monitoring therapeutic responses in intratympanic gentamicin-therapy.
2. Söderman AC, Bagger-Sjöbäck D, Bergenius J, Langius A. Factors influencing quality of life in patients with Ménière's disease, identified by a multidimensional approach. Otol Neurotol 2002; 23: 941-8.
3. Chia SH, Gamst AC, Anderson JP, Harris JP. Intratympanic gentamicin therapy for Ménière's disease: a meta-analysis. Otol Neurotol 2004; 25: 544-52.
4. Silverstein H, Wazen J, Van Ess MJ, Daugherty J, Alameda YA. Intratympanic gentamicin treatment of patients with Ménière's disease with normal hearing. Otolaryngol Head Neck Surg 2010; 142: 570-5
5. Driscoll CL, Kasperbauer JL, Facer GW, Harner SG, Beatty CW. Low-dose intratympanic gentamicin and the treatment of Meniere's disease: preliminary results. Laryngoscope 1997; 107: 83-9.
6. Soto A, Labella T, Santos S, Río MD, Lirola A, Cabanas E, et al. The usefulness of computerized dynamic posturography for the study of equilibrium in patients with Meniere's disease: correlation with clinical and audiologic data. Hear Res 2004; 196: 26-32. 7. Kingma CM, Wit HP. Asymmetric vestibular evoked myogenic potentials in unilateral Menière patients. Eur Arch Otorhinolaryngol 2011; 268: 57–61.
8. Lange G, Maurer J, Mann W. Long-term results after interval therapy with intratympanic gentamicin for Menière's disease. Laryngoscope 2004; 114: 102-5.
9. Picciotti PM, Fiorita A, Di Nardo W, Quaranta N, Paludetti G, Maurizi M. VEMPs and dynamic posturography after intratympanic gentamycin in Menière's disease. J Vestib Res 2005; 15: 161-8.
10. Black FO, Paloski WH. Computerized dynamic posturography: What have we learned from space? Otolaryngol Head Neck Surg 1998; 118: S45-51.
11. Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Menière's disease. American Academy of Otolaryngology-Head and Neck Foundation, Inc. Otolaryngol Head Neck Surg 1995; 113: 181-5.
12. Banerjee AS, Johnson IJ. Intratympanic gentamicin for Ménière's disease: effect on quality of life as assessed by Glasgow benefit inventory. J Laryngol Otol 2006; 120: 827-31.
13. Salt AN, Gill RM, Plontke SK. Dependence of hearing changes on the dose of intratympanically applied gentamicin: a meta- analysis using mathematical simulations of clinical drug delivery protocols. Laryngoscope 2008; 118: 1793-800.
14. Minor LB. Intratympanic gentamicin for control of vertigo in Meniere's disease: vestibular signs that specify completion of therapy. Am J Otol 1999; 20: 209-19.
15. Helling K, Schönfeld U, Clarke AH. Treatment of Ménière's disease by low- dosage intratympanic gentamicin application: effect on otolith function. Laryngoscope 2007; 117: 2244-50.
16. Chung WH, Chung KW, Kim JH, Cho YS, Hong SH. Effects of a single intratympanic gentamicin injection on Meniere's disease. Acta Otolaryngol Suppl 2007; (558): 61-6.
17. Ozluoglu LN, Akkuzu G, Ozgirgin N, Tarhan E. Reliability of the vestibular evoked myogenic potential test in assessing intratympanic gentamicin therapy in Meniere's disease. Acta Otolaryngol 2008; 128: 422-6.
18. Abou-Halawa AS, Poe DS. Efficacy of increased gentamicin concentration for intratympanic injection therapy in Ménière's disease. Otol Neurotol 2002; 23: 494-502.
19. Harner SG, Driscoll CL, Facer GW, Beatty CW, McDonald TJ. Long-term follow-up of transtympanic gentamicin for Ménière's syndrome. Otol Neurotol 2001; 22: 210-4.
20. Sennaroglu L, Sennaroglu G, Gursel B, Dini FM. Intratympanic dexamethasone, intratympanic gentamicin, and endolymphatic sac surgery for intractable vertigo in Meniere's disease. Otolaryngol Head Neck Surg 2001; 125: 537-43.
21. Adams ME, Heidenreich KD, Kileny PR. Audiovestibular testing in patients with Meniere's disease. Otolaryngol Clin North Am 2010; 43: 995-1009.
22. Janky KL, Shepard N. Vestibular evoked myogenic potential (VEMP) testing: normative threshold response curves and effects of age. J Am Acad Audiol 2009; 20: 514-22.
23. Gode S, Celebisoy N, Akyuz A, Gulec F, Karapolat H, Bilgen C, et al. Single-shot, low- dose intratympanic gentamicin in Ménière disease: role of vestibular-evoked myogenic potentials and caloric test in the prediction of outcome. Am J Otolaryngol 2011; 32(5): 412-6.
24. De Waele C, Meguenni R, Freyss G, Zamith F, Bellalimat N, Vidal PP, et al. Intratympanic gentamicin injections for Meniere disease: vestibular hair cell impairment and regeneration. Neurology 2002; 59: 1442-4.
25. Welgampola MS, Colebatch JG. Characteristics and clinical applications of vestibular-evoked myogenic potentials. Neurology 2005; 64: 1682-8.
26. Timmer FC, Zhou G, Guinan JJ, Kujawa SG, Herrmann BS, Rauch SD. Vestibular evoked myogenic potential (VEMP) in patients with Ménière's disease with drop attacks. Laryngoscope 2006; 116: 776-9.
27. Cohen-Kerem R, Kisilevsky V, Einarson TR, Kozer E, Koren G, Rutka JA. Intratympanic gentamicin for Menière's disease: a meta- analysis. Laryngoscope 2004; 114: 2085-91.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.